Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

Study shows how rare but serious post-COVID-19 complication develops in children, adolescents

A multidisciplinary team from MassGeneral Hospital for Children (MGHfC), Brigham and Women's Hospital and other institutions have identified the mechanism of how an extremely rare but serious post-COVID-19 complication develops in children and adolescents.

26 May 2021

Moderna's COVID vaccine proves effective against South African variant in primates

Researchers in the United States have demonstrated the efficacy of Moderna’s coronavirus disease 2019 (COVID-19) vaccine at protecting against the South African B.1.351 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in non-human primates.

26 May 2021

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

A new study aims to identify antibody-based biomarkers associated with the humoral immune response that could be a standard CoP candidate for COVID-19. Further, standardization of research methods to measure these biomarkers has also been conducted.

25 May 2021

Modeling the risk of SARS-CoV-2 outbreaks upon lifting non-pharmaceutical interventions (NPIs)

In a paper recently uploaded to the preprint server medRxiv* by Sachak-Patwa et al. (May 22nd, 2021), mathematical models are developed to assess the probability and impact of such localized outbreaks, accounting for changing general immunity levels in the population as vaccines are distributed.

25 May 2021

Person infected with SARS-CoV-2 can transmit infection to three to five other people

What started as the preliminary analysis of routine laboratory data has since evolved into the largest-ever study of viral load levels in patients with SARS-CoV-2.

25 May 2021

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

A team of international scientists recently conducted a randomized clinical trial to assess the safety and efficacy profiles of a novel probiotic formulation in symptomatic coronavirus disease 2019 (COVID-19) patients. The findings indicate that the probiotic formulation is highly effective in reducing symptom severity in COVID-19 patients without causing any adverse events.

25 May 2021

Human T cells can target more than 1,400 sites on SARS-CoV-2 virus

In a new paper, scientists from La Jolla Institute for Immunology (LJI) bring together research findings from COVID-19 researchers around the world.

25 May 2021

New study may pave way for novel therapeutic strategies for COVID-19

An international and multidisciplinary team led by researchers at the University of Oxford, University of Glasgow, and University of Heidelberg, has uncovered the interactions that SARS-CoV-2 RNA establishes with the host cell, many of which are fundamental for infection.

25 May 2021

Study shows how neutralizing antibodies are produced after SARS-CoV-2 infection

A research group from Osaka University led by Professor Hisashi Arase and consisting of researchers from the Research Institute for Microbial Diseases, the Institute for Protein Research, the Immunology Frontier Research Center, the Center for Infectious Diseases, and the Graduate School of Medicine has discovered for the first time that both neutralizing antibodies that protect against infection as well as infection-enhancing antibodies that increase infectivity are produced after infection with SARS-CoV-2 by analyzing antibodies derived from COVID-19 patients.

25 May 2021

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

New research – by scientists at the University of Chicago, Johns Hopkins School of Medicine and the University of Iowa in the USA – describes a novel COVID-19 vaccine candidate that has achieved impressive immunologic results in mouse studies.

25 May 2021

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Since COVID-19 was first detected in December 2019 in Wuhan, China, many different variants of its causative virus – SARS-CoV-2 – have emerged. Through increased viral fitness, some of these have risen to predominance over earlier variants in a remarkably short period of time. New research, by a team of scientists at major institutions in France, examines the reasons behind this phenomenon in one such variant of concern (VOC), the so-called UK variant.

25 May 2021

New testing protocol for SARS-CoV-2 can process thousands of samples within 48 hours

Researchers at the Vienna BioCenter designed a testing protocol for SARS-CoV-2 that can process tens of thousands of samples in less than 48 hours. The method, called SARSeq, is published in the journal Nature Communications and could be adapted to many more pathogens.

25 May 2021

Could 6′,6′-difluoro-aristeromycin (DFA) have broad-spectrum antiviral potential against coronaviruses?

Researchers at the Leiden University Medical Center demonstrated that low-micromolar concentrations of 6′,6′-difluoro24 aristeromycin (DFA), an adenosine nucleoside analog, strongly inhibits the replication of Middle East respiratory syndrome coronavirus (MERS-CoV) in a cell-based infection assay.

25 May 2021

Corporations encourage employee vaccination but stop short of mandates

Many of the companies with the largest number of employees say they'll do almost anything to encourage their employees to get vaccinated.

25 May 2021

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

The aim of this study investigates the impact of different types of vaccines on the anti-SARS-CoV-2 Immunoglobulin A (IgA) and Immunoglobulin G (IgG) antibody levels found in human milk.

25 May 2021

Heterologous prime-boost immunization with AstraZeneca and Pfizer COVID-19 vaccines safe and well-tolerated, study finds

A team of scientists from Germany has recently evaluated the reactogenicity profile of heterologous ChAdOx1 nCoV-19/BNT162b2 prime-boost vaccination among healthcare workers. The findings reveal that a 12-week interval regimen of heterologous vaccination is well-tolerated among participants. The study is currently available on the medRxiv* preprint server.

25 May 2021

DEFINE: Trial designed to test repurposed treatments in patients with COVID-19

A team of scientists from the United Kingdom has designed an experimental medicine trial to evaluate the safety/tolerability, and efficacy profiles of a panel of candidate repurposed therapies in coronavirus disease 2019 (COVID-19) patients. A detailed outline of the trial is currently available on the medRxiv* preprint server.

25 May 2021

Research looks at viral presence around hospitalized COVID-19 patients

Researchers in Canada aimed to determine the burden of SARS-CoV-2 in the air and on surfaces in the rooms of patients hospitalized with COVID-19.

25 May 2021

Discovery of novel SARS-related coronaviruses in bats

In a recent study published on the bioRxiv* server, Peng Zhou, Zheng-Li Shi and colleagues at the Wuhan Institute of Virology, with collaboration from scientists at the University of Chinese Academy of Sciences in China, have identified a new lineage of SARS-related coronaviruses that utilize bat angiotensin-converting enzyme 2 (ACE2) receptors for cell entry, which is the same receptor used by SARS-CoV-2 to infect host cells.

25 May 2021

Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

Study shows how rare but serious post-COVID-19 complication develops in children, adolescents

Moderna's COVID vaccine proves effective against South African variant in primates

Study attempts to standardize humoral immune Correlates of Protection (CoP) in COVID-19

Modeling the risk of SARS-CoV-2 outbreaks upon lifting non-pharmaceutical interventions (NPIs)

Person infected with SARS-CoV-2 can transmit infection to three to five other people

Researchers develop a novel probiotic formulation with high anti-SARS-CoV-2 potency

Human T cells can target more than 1,400 sites on SARS-CoV-2 virus

New study may pave way for novel therapeutic strategies for COVID-19

Study shows how neutralizing antibodies are produced after SARS-CoV-2 infection

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

Next-generation SARS-CoV-2 subunit vaccine candidate elicits powerful immunity in preclinical trials

SARS-CoV-2 UK variant may induce more inflammation, study suggests

New testing protocol for SARS-CoV-2 can process thousands of samples within 48 hours

Could 6′,6′-difluoro-aristeromycin (DFA) have broad-spectrum antiviral potential against coronaviruses?

Corporations encourage employee vaccination but stop short of mandates

Do vaccinations result in anti-SARS-CoV-2 antibodies in human milk?

Heterologous prime-boost immunization with AstraZeneca and Pfizer COVID-19 vaccines safe and well-tolerated, study finds

DEFINE: Trial designed to test repurposed treatments in patients with COVID-19

Research looks at viral presence around hospitalized COVID-19 patients

Discovery of novel SARS-related coronaviruses in bats

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Coronavirus Disease COVID 19 News and Research

Latest Coronavirus Disease COVID 19 News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in